InMed Pharmaceuticals Inc. INM
InMed Pharmaceuticals Inc. (Nasdaq: INM) is a CNS/neurology/psychiatry drug developer. Its lead program, INM-901, is in Pre-clinical for Alzheimer's disease.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| INM-755 (cannabinol) cream | Epidermolysis Bullosa (EB) | small molecule | Phase 2 |
| INM-901 | Alzheimer's disease | small molecule | Pre-clinical |
| INM-089 | dry Age-Related Macular Degeneration (dry AMD) | small molecule | Pre-clinical |
Recent results and decisions
- Nov 3, 2026n/a InMed completed a pre-IND meeting with the FDA and reached alignment on the next steps in the development of INM-901 for Alzheimer's disease.
During the quarter, InMed completed a pre-IND meeting with the FDA and reached alignment on the next steps in the development of INM-901 in the treatment of Alzheimer's disease.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.